Healthcare
Live Price
Offline$1.16
-1.69% today
1Y Change
-7.20%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pliant Therapeutics, Inc. (PLRX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.16 and down 7.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +30.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +30.0%, free cash flow +19.2% with operating margin 0.0% and ROIC -73.2%. Stock Foundry combines PLRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLRX Max Drawdown
-41.71%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.6M
-21.8% YoY
FY Net Income
-$97.3M
+21.1% YoY
Free Cash Flow
-$77.4M
+19.7% YoY
Revenue Growth
+0.0%
EPS Growth
+30.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 10M | 8M |
| Gross Profit | -2M | 0 | 2M | 10M | 8M |
| Operating Income | -150M | -228M | -184M | -127M | -98M |
| EBITDA | -148M | -205M | -158M | -119M | -96M |
| Net Income | -149M | -210M | -161M | -123M | -97M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 45M | 71M | 63M | 34M | 52M |
| Total Assets | 225M | 397M | 512M | 351M | 221M |
| Total Liabilities | 44M | 93M | 39M | 37M | 22M |
| Shareholder Equity | 181M | 304M | 474M | 313M | 199M |
| Total Debt | 29M | 60M | 11M | 16M | 7M |
| Net Debt | -16M | -11M | -52M | -18M | -44M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
75M
+20.3% YoY
Capital Expenditures
2M
-11.0% YoY
Free Cash Flow
77M
+19.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-69.6%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.